Relay Therapeutics, Inc. (RLAY): Total Liabilities
$54.27M
As of 2025-12-31
$77.45M
As of 2026-06-30
-28.7%
3-year compound annual growth
+8.2%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $54.27M | -42.0% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $93.50M | +1.7% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $91.98M | -38.5% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $149.55M | +35.2% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $110.64M | +202.8% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $36.54M | +2.3% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $35.73M | n/a | 2021-03-25, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $54.27M | -42.0% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $69.24M | +91.2% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $91.52M | n/m |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $21.54M | +92.0% |
| Alector, Inc. (ALEC) | 2025-12-31 | $262.59M | -23.1% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $53.19M | -11.9% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $105.67M | -18.8% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $17.20M | +47.7% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $96.38M | +8.5% |
Compare RLAY, LCTX, PTHS, LENZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗